semaglutide (Ozempic)

Original post, click here

Generic Name: semaglutide

Brand Name: Ozempic

Manufacturer: Novo Nordisk Canada Inc.

Indications: Diabetes mellitus, type 2

Manufacturer Requested Reimbursement Criteria1:

​For the treatment of adults patients with type 2 diabetes to improve glycemic control, in combination with metformin (second line treatment) and in combination with metformin and sulfonylurea (third line treatment).

Submission Type: New

Project Status: Pending

Call For Patient Input: October 26, 2018

Patient Input Closed: December 14, 2018

Anticipated Date: November 23, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback